Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.34 USD | -0.84% | -0.74% | +42.93% |
Jun. 04 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
Jun. 03 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.93% | 2.3B | |
+75.69% | 12.57B | |
-25.35% | 7.28B | |
+15.77% | 7.2B | |
+14.52% | 5.47B | |
-18.50% | 4.73B | |
+14.91% | 4.09B | |
-23.67% | 3.78B | |
-0.37% | 2.03B | |
-0.57% | 1.78B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- Novocure Names Nicolas Leupin as Chief Medical Officer